Thomas Greuter1, Luc Biedermann1, Gerhard Rogler1, Bernhard Sauter2, Frank Seibold3. 1. Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland. 2. Gastrozentrum Hirslanden, Hirslanden Private Clinic Group, Zurich, Switzerland. 3. Division of Gastroenterology and Hepatology, Tiefenauspital Bern, Bern, Switzerland.
Abstract
BACKGROUND AND AIMS: The published data about the efficacy of the intercellular adhesion molecule-1 (ICAM-1) antisense oligonucleotide termed alicaforsen in inflammatory bowel disease (IBD) is rather inconsistent. This case series analyzes its efficacy in chronic refractory pouchitis, after proctocolectomy. METHODS: We performed a retrospective analysis on all patients who had received at least one dose of alicaforsen for IBD at three referral centers in Switzerland. We assessed the drug's efficacy in patients treated for chronic refractory pouchitis, by comparing the clinical and/or endoscopic disease activity at baseline with a 2-3-month follow-up visit. RESULTS: We identified 22 patients who had received at least one dose. Among them, 13 patients were being treated for chronic refractory pouchitis. These patients had a median age of 38.0 years (95% CI 21.0-69.0) and five were female (38.5%). The median time since pouch surgery was 102.5 months (95% CI 16.0-288.0), with a median pouchitis duration of 16.0 months (95% CI 4.0-216.0). At 2-3 months after therapy, clinical and endoscopic disease activity was significantly reduced (stool frequency 9.0 versus 6.0, the Pouchitis Disease Activity Index (PDAI) clinical subscore was 4.0 versus 1.0, and the endoscopic disease activity was 4.0 versus 2.0). Clinical improvement was achieved in 11 out of 13 pouchitis patients (84.6%); however, a relapse was observed in nine of these patients (81.8%). The median time from clinical improvement to relapse was 16 weeks (95% CI 9.0-23.0). CONCLUSIONS: Alicaforsen seemed to be efficacious in inducing clinical and/or endoscopic improvement in chronic refractory pouchitis and may be a promising treatment alternative in those patients; however, given the high proportion of relapse, one 6-week course of alicaforsen may not be sufficient.
BACKGROUND AND AIMS: The published data about the efficacy of the intercellular adhesion molecule-1 (ICAM-1) antisense oligonucleotide termed alicaforsen in inflammatory bowel disease (IBD) is rather inconsistent. This case series analyzes its efficacy in chronic refractory pouchitis, after proctocolectomy. METHODS: We performed a retrospective analysis on all patients who had received at least one dose of alicaforsen for IBD at three referral centers in Switzerland. We assessed the drug's efficacy in patients treated for chronic refractory pouchitis, by comparing the clinical and/or endoscopic disease activity at baseline with a 2-3-month follow-up visit. RESULTS: We identified 22 patients who had received at least one dose. Among them, 13 patients were being treated for chronic refractory pouchitis. These patients had a median age of 38.0 years (95% CI 21.0-69.0) and five were female (38.5%). The median time since pouch surgery was 102.5 months (95% CI 16.0-288.0), with a median pouchitis duration of 16.0 months (95% CI 4.0-216.0). At 2-3 months after therapy, clinical and endoscopic disease activity was significantly reduced (stool frequency 9.0 versus 6.0, the Pouchitis Disease Activity Index (PDAI) clinical subscore was 4.0 versus 1.0, and the endoscopic disease activity was 4.0 versus 2.0). Clinical improvement was achieved in 11 out of 13 pouchitispatients (84.6%); however, a relapse was observed in nine of these patients (81.8%). The median time from clinical improvement to relapse was 16 weeks (95% CI 9.0-23.0). CONCLUSIONS:Alicaforsen seemed to be efficacious in inducing clinical and/or endoscopic improvement in chronic refractory pouchitis and may be a promising treatment alternative in those patients; however, given the high proportion of relapse, one 6-week course of alicaforsen may not be sufficient.
Authors: Bruce Yacyshyn; William Y Chey; Mark K Wedel; Rosie Z Yu; David Paul; Emil Chuang Journal: Clin Gastroenterol Hepatol Date: 2007-02 Impact factor: 11.382
Authors: B R Yacyshyn; C Barish; J Goff; D Dalke; M Gaspari; R Yu; J Tami; F A Dorr; K L Sewell Journal: Aliment Pharmacol Ther Date: 2002-10 Impact factor: 8.171
Authors: B R Yacyshyn; W Y Chey; J Goff; B Salzberg; R Baerg; A L Buchman; J Tami; R Yu; E Gibiansky; W R Shanahan Journal: Gut Date: 2002-07 Impact factor: 23.059
Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: S K Miroshnichenko; O A Patutina; E A Burakova; B P Chelobanov; A A Fokina; V V Vlassov; S Altman; M A Zenkova; D A Stetsenko Journal: Proc Natl Acad Sci U S A Date: 2019-01-08 Impact factor: 11.205
Authors: Panagiota Bouti; Steven D S Webbers; Susanna C Fagerholm; Ronen Alon; Markus Moser; Hanke L Matlung; Taco W Kuijpers Journal: Front Immunol Date: 2021-02-18 Impact factor: 7.561
Authors: Dimitrios Nikolakis; Floris A E de Voogd; Maarten J Pruijt; Joep Grootjans; Marleen G van de Sande; Geert R D'Haens Journal: Int J Mol Sci Date: 2022-02-06 Impact factor: 5.923